CL2019001993A1 - Inhibidores selectivos de jak1. - Google Patents
Inhibidores selectivos de jak1.Info
- Publication number
- CL2019001993A1 CL2019001993A1 CL2019001993A CL2019001993A CL2019001993A1 CL 2019001993 A1 CL2019001993 A1 CL 2019001993A1 CL 2019001993 A CL2019001993 A CL 2019001993A CL 2019001993 A CL2019001993 A CL 2019001993A CL 2019001993 A1 CL2019001993 A1 CL 2019001993A1
- Authority
- CL
- Chile
- Prior art keywords
- jak1
- selective inhibitors
- document
- formula
- disclosed
- Prior art date
Links
- 229940124639 Selective inhibitor Drugs 0.000 title 1
- 101150079478 jak1 gene Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
SE DESVELAN EN EL PRESENTE DOCUMENTO COMPUESTOS DE FÓRMULA (I), Y SALES FARMACÉUTICAMENTE ACEPTABLES DE LOS MISMOS, EN LA QUE R1-R8 TIENEN CUALQUIERA DE LOS SIGNIFICADOS DEFINIDOS EN EL PRESENTE DOCUMENTO. ADEMÁS, SE DESVELAN COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN COMPUESTOS DE FÓRMULA (I) Y MÉTODOS DE USO DE LOS MISMOS.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762447057P | 2017-01-17 | 2017-01-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2019001993A1 true CL2019001993A1 (es) | 2019-12-27 |
Family
ID=61024756
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2019001993A CL2019001993A1 (es) | 2017-01-17 | 2019-07-15 | Inhibidores selectivos de jak1. |
Country Status (36)
Country | Link |
---|---|
US (3) | US10961228B2 (es) |
EP (2) | EP3571192B1 (es) |
JP (3) | JP6986086B2 (es) |
KR (2) | KR102585048B1 (es) |
CN (2) | CN110461830B (es) |
AR (1) | AR110753A1 (es) |
AU (1) | AU2018209667B2 (es) |
CA (1) | CA3049175A1 (es) |
CL (1) | CL2019001993A1 (es) |
CO (1) | CO2019007888A2 (es) |
CR (1) | CR20190332A (es) |
DK (1) | DK3571192T3 (es) |
DO (1) | DOP2019000184A (es) |
EA (1) | EA037067B1 (es) |
EC (1) | ECSP19051352A (es) |
ES (1) | ES2938648T3 (es) |
FI (1) | FI3571192T3 (es) |
HR (1) | HRP20230069T1 (es) |
HU (1) | HUE061064T2 (es) |
IL (1) | IL267851B (es) |
JO (1) | JOP20190174B1 (es) |
LT (1) | LT3571192T (es) |
MA (1) | MA47301B1 (es) |
MX (2) | MX2019008435A (es) |
NI (1) | NI201900077A (es) |
PE (1) | PE20191108A1 (es) |
PH (1) | PH12019501639A1 (es) |
PL (1) | PL3571192T3 (es) |
PT (1) | PT3571192T (es) |
RS (1) | RS63981B1 (es) |
SG (1) | SG11201906222WA (es) |
SI (1) | SI3571192T1 (es) |
TW (1) | TWI753089B (es) |
UA (1) | UA124246C2 (es) |
WO (1) | WO2018134213A1 (es) |
ZA (1) | ZA201906875B (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2938648T3 (es) * | 2017-01-17 | 2023-04-13 | Astrazeneca Ab | Inhibidores selectivos de JAK1 |
HUE056472T2 (hu) | 2017-01-26 | 2022-02-28 | Hanmi Pharm Ind Co Ltd | Pirimidin vegyület és annak gyógyszerészeti felhasználása |
MX2021000611A (es) * | 2018-07-18 | 2021-04-13 | Astrazeneca Ab | Una sal de xinafoato de un compuesto inhibidor de jak. |
AU2019344878B2 (en) * | 2018-09-21 | 2022-08-11 | Shanghai Ennovabio Pharmaceuticals Co., Ltd. | Aromatic heterocyclic compound with kinase inhibitory activity |
KR20220003537A (ko) | 2019-04-19 | 2022-01-10 | 디잘 (지앙수) 파마슈티칼 씨오., 리미티드 | Jak1 선택적 키나제 억제제 |
WO2021207302A1 (en) * | 2020-04-09 | 2021-10-14 | Disarm Therapeutics, Inc. | Indazole derivatives as inhibitors of sarm1 |
US20240025884A1 (en) * | 2022-07-05 | 2024-01-25 | Dong-A St Co., Ltd. | Compounds as gcn2 inhibitors, pharmaceutical compositions and uses thereof |
CN115260128B (zh) * | 2022-09-21 | 2022-12-09 | 苏州凯瑞医药科技有限公司 | 一种新型jak抑制剂关键中间体的制备方法 |
WO2024150110A1 (en) * | 2023-01-11 | 2024-07-18 | Pfizer Inc. | Compositions and methods for the treatment and/or prevention of type 1 diabetes |
CN115974845B (zh) * | 2023-01-19 | 2024-09-20 | 奥锐特药业股份有限公司 | 奥希替尼中间体的制备方法 |
US20240307353A1 (en) * | 2023-03-16 | 2024-09-19 | Incyte Corporation | Jak1 pathway inhibitors for the treatment of asthma |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2005295788A1 (en) * | 2004-10-13 | 2006-04-27 | Wyeth | N-benzenesulfonyl substituted anilino-pyrimidine analogs |
CN101421250A (zh) * | 2006-01-30 | 2009-04-29 | 埃克塞里艾克西斯公司 | 作为jak-2调节剂的4-芳基-2-氨基-嘧啶或4-芳基-2-氨基烷基-嘧啶及包含它们的药物组合物 |
WO2009046416A1 (en) * | 2007-10-05 | 2009-04-09 | Targegen Inc. | Anilinopyrimidines as jak kinase inhibitors |
GB0805477D0 (en) | 2008-03-26 | 2008-04-30 | Univ Nottingham | Pyrimidines triazines and their use as pharmaceutical agents |
UA110324C2 (en) * | 2009-07-02 | 2015-12-25 | Genentech Inc | Jak inhibitory compounds based on pyrazolo pyrimidine |
AU2011224484A1 (en) | 2010-03-10 | 2012-09-27 | Incyte Holdings Corporation | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors |
TW201217387A (en) * | 2010-09-15 | 2012-05-01 | Hoffmann La Roche | Azabenzothiazole compounds, compositions and methods of use |
EP3060234A1 (en) | 2013-10-24 | 2016-08-31 | AbbVie Inc. | Jak1 selective inhibitor and uses thereof |
CA2995430C (en) * | 2015-09-25 | 2023-07-11 | Dizal (Jiangsu) Pharmaceutical Co., Limited | Compounds and methods for inhibiting jak |
ES2938648T3 (es) * | 2017-01-17 | 2023-04-13 | Astrazeneca Ab | Inhibidores selectivos de JAK1 |
-
2018
- 2018-01-16 ES ES18701296T patent/ES2938648T3/es active Active
- 2018-01-16 US US16/478,168 patent/US10961228B2/en active Active
- 2018-01-16 LT LTEPPCT/EP2018/051038T patent/LT3571192T/lt unknown
- 2018-01-16 SG SG11201906222WA patent/SG11201906222WA/en unknown
- 2018-01-16 EP EP18701296.8A patent/EP3571192B1/en active Active
- 2018-01-16 RS RS20230130A patent/RS63981B1/sr unknown
- 2018-01-16 MX MX2019008435A patent/MX2019008435A/es unknown
- 2018-01-16 AU AU2018209667A patent/AU2018209667B2/en active Active
- 2018-01-16 PL PL18701296.8T patent/PL3571192T3/pl unknown
- 2018-01-16 KR KR1020197023855A patent/KR102585048B1/ko active IP Right Grant
- 2018-01-16 UA UAA201909176A patent/UA124246C2/uk unknown
- 2018-01-16 WO PCT/EP2018/051038 patent/WO2018134213A1/en unknown
- 2018-01-16 CN CN201880018044.3A patent/CN110461830B/zh active Active
- 2018-01-16 CR CR20190332A patent/CR20190332A/es unknown
- 2018-01-16 FI FIEP18701296.8T patent/FI3571192T3/fi active
- 2018-01-16 PE PE2019001401A patent/PE20191108A1/es unknown
- 2018-01-16 EP EP22209765.1A patent/EP4219470A1/en active Pending
- 2018-01-16 JP JP2019537377A patent/JP6986086B2/ja active Active
- 2018-01-16 KR KR1020237032917A patent/KR102659213B1/ko active IP Right Grant
- 2018-01-16 CN CN202211243959.9A patent/CN115925693A/zh active Pending
- 2018-01-16 HU HUE18701296A patent/HUE061064T2/hu unknown
- 2018-01-16 MA MA47301A patent/MA47301B1/fr unknown
- 2018-01-16 DK DK18701296.8T patent/DK3571192T3/da active
- 2018-01-16 CA CA3049175A patent/CA3049175A1/en active Pending
- 2018-01-16 PT PT187012968T patent/PT3571192T/pt unknown
- 2018-01-16 JO JOP/2019/0174A patent/JOP20190174B1/ar active
- 2018-01-16 HR HRP20230069TT patent/HRP20230069T1/hr unknown
- 2018-01-16 SI SI201830849T patent/SI3571192T1/sl unknown
- 2018-01-16 EA EA201991700A patent/EA037067B1/ru unknown
- 2018-01-17 AR ARP180100104A patent/AR110753A1/es unknown
- 2018-01-17 TW TW107101685A patent/TWI753089B/zh active
-
2019
- 2019-07-04 IL IL267851A patent/IL267851B/en unknown
- 2019-07-15 PH PH12019501639A patent/PH12019501639A1/en unknown
- 2019-07-15 MX MX2022002976A patent/MX2022002976A/es unknown
- 2019-07-15 CL CL2019001993A patent/CL2019001993A1/es unknown
- 2019-07-17 DO DO2019000184A patent/DOP2019000184A/es unknown
- 2019-07-17 EC ECSENADI201951352A patent/ECSP19051352A/es unknown
- 2019-07-17 NI NI201900077A patent/NI201900077A/es unknown
- 2019-07-23 CO CONC2019/0007888A patent/CO2019007888A2/es unknown
- 2019-10-18 ZA ZA2019/06875A patent/ZA201906875B/en unknown
-
2021
- 2021-03-01 US US17/188,097 patent/US11897869B2/en active Active
- 2021-11-26 JP JP2021191658A patent/JP7394820B2/ja active Active
-
2023
- 2023-10-20 JP JP2023180744A patent/JP2024010041A/ja active Pending
- 2023-12-13 US US18/538,067 patent/US20240208947A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2019001993A1 (es) | Inhibidores selectivos de jak1. | |
CO2020007244A2 (es) | Inhibidores de kras g12c | |
CL2020000075A1 (es) | Carboxamidas como moduladores de los canales de sodio. | |
CL2017000902A1 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
SV2018005687A (es) | Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer | |
CL2019002609A1 (es) | Compuestos heterocíclicos útiles como inhibidores dobles atx/ca. | |
UY37205A (es) | Inhibidores de bromodominios | |
CO2017002998A2 (es) | Derivados de tetrahidronaftaleno que inhiben la proteína mcl-1 | |
CO2018000631A2 (es) | Compuestos bicíclicos como inhibidores de atx | |
CR20150436A (es) | Nuevos octahidro-pirrolo[3,4-c]-pirrol y -piridina-fenilo | |
CO2017011151A2 (es) | Nuevos compuestos bicíclicos como inhibidores de la atx | |
CR20160419A (es) | Nuevos compuestos biciclicos | |
CO7121325A2 (es) | Nuevos diazaespirocicloalcanos y azaespirocicloalcanos | |
CR20150524A (es) | Compuestos de heteroarilo y sus usos | |
CL2017000820A1 (es) | Compuestos de aminopurina sustituida, composiciones de los mismos, y metodos de tratamiento con los mismos | |
GT201700023A (es) | Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias | |
DOP2015000170A (es) | Compuestos químicos | |
CL2017000682A1 (es) | Compuestos novedosos de imidazopiridazina y su uso. | |
CO2020004977A2 (es) | Compuestos bicíclicos para su uso como inhibidores de la ripi quinasa | |
CR20160070A (es) | Compuestos de triazolopiridina, composiciones y métodos de uso de los mismos | |
DOP2018000066A (es) | Compuestos útiles para inhibir ror-gamma-t | |
UY36117A (es) | Composiciones farmacéuticas para el tratamiento de enfermedades infecciosas. | |
GT201300225A (es) | Tieno (2,3-d) derivados de pirimidina y su uso para el tratamiento de la arritmia | |
UY36958A (es) | Compuestos para administración intracelular | |
UY36464A (es) | Compuestos de quinazolina |